MDGL

Madrigal Pharmaceuticals, Inc. NASDAQ Listed Feb 6, 2007

Healthcare ·Biotechnology ·US · madrigalpharma.com

$538.95

After hrs $539.73 +0.00%

Mkt Cap $12.4B

52w Low $265.00 78.3% of range 52w High $615.00

50d MA $485.43 200d MA $470.85

P/E (TTM) -40.0x

EV/EBITDA -50.0x

P/B 19.1x

Debt/Equity 0.6x

ROE -47.8%

P/FCF -68.8x

RSI (14) —

ATR (14) —

Beta -1.01

50d MA $485.43

200d MA $470.85

Avg Volume 351.7K

About

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic ste…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 19, 2026	BMO	0.04	-2.57	-6525.0%	491.49	-8.0%	-11.1%	-11.5%	-10.9%	-10.5%	-11.5%	—
Nov 4, 2025	BMO	-2.04	-5.08	-149.4%	412.35	-1.5%	+7.8%	+15.4%	+18.5%	+18.7%	+20.3%	—
Aug 5, 2025	BMO	-3.48	-1.90	+45.4%	312.11	+12.1%	+8.6%	+8.3%	+9.7%	+10.8%	+12.0%	—
May 1, 2025	BMO	-3.62	-3.32	+8.3%	333.91	+4.5%	-1.9%	-5.5%	-8.2%	-11.6%	-10.5%	—
Feb 26, 2025	BMO	-4.32	-2.71	+37.3%	309.49	+8.2%	+15.0%	+8.5%	+10.3%	+1.3%	+3.8%	—
Oct 31, 2024	BMO	-6.94	-4.92	+29.1%	215.93	+13.8%	+20.1%	+48.0%	+53.4%	+56.4%	+56.6%	—
Aug 7, 2024	BMO	-7.55	-7.10	+6.0%	266.56	-6.6%	-12.2%	-8.6%	-11.1%	-9.2%	-8.6%	—
May 7, 2024	BMO	-6.06	-7.38	-21.8%	235.57	-5.8%	-7.5%	-11.7%	-12.2%	-12.9%	-10.3%	—
Feb 28, 2024	BMO	-5.32	-5.68	-6.8%	239.80	-0.3%	+6.0%	-1.5%	+4.9%	+2.8%	+3.6%	—
Nov 6, 2023	BMO	-4.78	-5.34	-11.7%	146.89	-2.4%	+0.3%	+3.6%	-2.4%	-7.2%	-5.5%	—
Aug 8, 2023	BMO	-4.47	-4.69	-4.9%	179.49	-2.5%	-5.8%	-6.0%	-4.3%	-4.5%	-3.4%	—
May 9, 2023	BMO	-4.98	-4.23	+15.1%	308.87	-0.8%	-3.0%	-5.4%	-6.7%	-5.2%	-6.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 20	BofA Securities	Maintains	Neutral → Neutral	—	$436.87	$435.01	-0.4%	-0.4%	+0.2%	+0.7%	-0.4%	+2.1%
Jan 20	Citizens	Maintains	Market Outperform → Market Outperform	—	$501.68	$491.94	-1.9%	+0.7%	-0.9%	-0.7%	-4.2%	-0.5%
Dec 19	Piper Sandler	Maintains	Overweight → Overweight	—	$544.41	$552.42	+1.5%	+8.6%	+10.7%	+10.6%	+10.7%	+10.0%
Dec 11	B. Riley Securities	Maintains	Buy → Buy	—	$552.47	$559.13	+1.2%	+3.4%	+3.4%	+1.5%	+0.4%	-1.1%
Nov 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$542.12	$542.85	+0.1%	+1.1%	+8.4%	+9.2%	+10.9%	+10.1%
Nov 20	Oppenheimer	Maintains	Outperform → Outperform	—	$555.60	$562.71	+1.3%	-2.4%	-1.4%	+5.8%	+6.6%	+8.2%
Nov 19	Truist	Maintains	Buy → Buy	—	$558.99	$554.39	-0.8%	-0.6%	-3.0%	-2.0%	+5.2%	+5.9%
Nov 13	Canaccord Genuity	Maintains	Buy → Buy	—	$528.94	$527.37	-0.3%	-2.6%	+0.1%	+4.6%	+5.7%	+5.0%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$495.88	$491.39	-0.9%	+9.2%	+6.7%	+3.8%	+6.7%	+11.6%
Nov 5	Citizens	Maintains	Market Outperform → Market Outperform	—	$444.64	$450.90	+1.4%	+7.0%	+9.9%	+10.0%	+11.5%	+21.8%
Nov 5	Cantor Fitzgerald	Upgrade	Neutral → Overweight	—	$444.64	$450.90	+1.4%	+7.0%	+9.9%	+10.0%	+11.5%	+21.8%
Nov 3	BofA Securities	Upgrade	Underperform → Neutral	—	$418.90	$421.64	+0.7%	-1.6%	+6.1%	+13.6%	+16.6%	+16.8%
Oct 15	Piper Sandler	Maintains	Overweight → Overweight	—	$437.10	$444.33	+1.7%	-0.8%	+1.2%	+0.4%	+0.7%	-1.6%
Oct 10	Oppenheimer	Maintains	Outperform → Outperform	—	$428.30	$428.71	+0.1%	+0.3%	-0.1%	+2.1%	+1.2%	+3.2%
Sep 29	B. Riley Securities	Maintains	Buy → Buy	—	$424.23	$427.85	+0.9%	+4.4%	+8.1%	+5.9%	+6.0%	+4.4%
Sep 12	Canaccord Genuity	Maintains	Buy → Buy	—	$439.45	$439.99	+0.1%	-1.6%	-3.2%	-2.8%	-5.0%	+0.3%
Aug 26	TD Cowen	Maintains	Buy → Buy	—	$412.23	$412.69	+0.1%	+3.1%	+3.1%	+6.0%	+6.2%	+5.8%
Aug 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$379.55	$380.61	+0.3%	+3.2%	+7.3%	+9.3%	+8.6%	+11.9%
Aug 12	UBS	Maintains	Buy → Buy	—	$349.50	$352.48	+0.9%	+2.7%	+6.9%	+6.3%	+5.8%	+12.0%
Aug 6	Canaccord Genuity	Maintains	Buy → Buy	—	$338.91	$333.48	-1.6%	-0.2%	+1.0%	+2.0%	+3.1%	+5.9%
May 2	UBS	Maintains	Buy → Buy	—	$327.70	$329.86	+0.7%	-3.7%	-6.5%	-9.9%	-8.8%	-8.6%
May 2	Canaccord Genuity	Maintains	Buy → Buy	—	$327.70	$329.86	+0.7%	-3.7%	-6.5%	-9.9%	-8.8%	-8.6%
May 2	B. Riley Securities	Maintains	Buy → Buy	—	$327.70	$329.86	+0.7%	-3.7%	-6.5%	-9.9%	-8.8%	-8.6%
Apr 24	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$308.79	$309.17	+0.1%	+3.6%	+5.8%	+7.3%	+10.4%	+8.1%
Feb 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$355.88	$361.38	+1.5%	-5.7%	-4.1%	-11.9%	-9.7%	-2.4%
Feb 27	Citigroup	Maintains	Buy → Buy	—	$355.88	$361.38	+1.5%	-5.7%	-4.1%	-11.9%	-9.7%	-2.4%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$303.71	$304.80	+0.4%	-9.7%	-9.6%	-10.2%	-3.3%	+1.1%
Jan 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$333.39	$323.05	-3.1%	+1.7%	-8.9%	-17.8%	-17.7%	-18.2%
Nov 5	B. Riley Securities	Maintains	Neutral → Neutral	—	$331.32	$331.00	-0.1%	+1.9%	+2.1%	+7.1%	+5.8%	+2.5%
Nov 1	UBS	Maintains	Buy → Buy	—	$259.34	$274.98	+6.0%	+23.2%	+27.8%	+30.2%	+30.4%	+36.8%
Oct 23	Oppenheimer	Maintains	Outperform → Outperform	—	$203.59	$204.44	+0.4%	-0.5%	-0.3%	+3.5%	+6.6%	+7.0%
Oct 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$208.89	$208.20	-0.3%	-2.5%	-3.1%	-2.8%	+0.9%	+3.9%
Aug 8	Evercore ISI	Maintains	Outperform → Outperform	—	$234.08	$241.18	+3.0%	+4.1%	+1.2%	+3.4%	+4.1%	+3.9%
Aug 8	Citigroup	Maintains	Buy → Buy	—	$234.08	$241.18	+3.0%	+4.1%	+1.2%	+3.4%	+4.1%	+3.9%
Jul 16	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$279.95	$281.77	+0.7%	-2.2%	-3.8%	-0.3%	+2.6%	+2.5%
May 10	B. Riley Securities	Maintains	Neutral → Neutral	—	$206.92	$206.40	-0.3%	-0.8%	+2.1%	+2.0%	+2.3%	+5.0%
May 8	Citigroup	Maintains	Buy → Buy	—	$217.96	$211.52	-3.0%	-4.6%	-5.1%	-5.8%	-3.0%	-3.2%
May 8	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$217.96	$211.52	-3.0%	-4.6%	-5.1%	-5.8%	-3.0%	-3.2%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$217.96	$211.52	-3.0%	-4.6%	-5.1%	-5.8%	-3.0%	-3.2%
Mar 20	Evercore ISI	Maintains	Outperform → Outperform	—	$265.68	$267.50	+0.7%	-2.5%	-3.9%	-6.6%	-6.8%	-6.8%
Mar 15	Citigroup	Maintains	Buy → Buy	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	Oppenheimer	Maintains	Outperform → Outperform	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	Canaccord Genuity	Maintains	Buy → Buy	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	JMP Securities	Maintains	Outperform → Outperform	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	UBS	Maintains	Buy → Buy	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	TD Cowen	Maintains	Outperform → Outperform	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 15	B. Riley Securities	Upgrade	Sell → Neutral	—	$243.57	$293.90	+20.7%	+11.0%	+16.3%	+9.1%	+6.3%	+4.8%
Mar 14	Piper Sandler	Maintains	Overweight → Overweight	—	$272.98	$274.58	+0.6%	-10.8%	-1.0%	+3.8%	-2.7%	-5.1%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$260.15	$268.00	+3.0%	+1.0%	+4.9%	-6.4%	+3.9%	+8.9%

Recent Filings

8-K

Madrigal Pharmaceuticals, Inc. -- 8-K Filing

Madrigal Pharmaceuticals reported strong Q1 2026 results for its MASH-focused pipeline, with CEO Bill Sibold signaling positive momentum heading into the year.

May 6

8-K

Madrigal Pharmaceuticals, Inc. -- 8-K Filing

Madrigal Pharmaceuticals achieved $958.4 million in Rezdiffra sales for 2025 with over 36,250 patients and $988.6 million in cash, supporting its robust MASH pipeline development.

Feb 19

Data updated apr 26, 2026 11:39am · Source: massive.com